Stevens Capital Management LP Has $355,000 Stock Holdings in DaVita Inc. (NYSE:DVA)

Stevens Capital Management LP reduced its position in DaVita Inc. (NYSE:DVA) by 17.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,392 shares of the company’s stock after selling 698 shares during the period. Stevens Capital Management LP’s holdings in DaVita were worth $355,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in DaVita by 1.1% in the third quarter. Vanguard Group Inc. now owns 6,175,029 shares of the company’s stock valued at $583,725,000 after acquiring an additional 65,526 shares during the last quarter. Invesco Ltd. raised its holdings in shares of DaVita by 21.3% during the third quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares during the period. Deutsche Bank AG raised its holdings in shares of DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after acquiring an additional 885,195 shares during the last quarter. Lazard Asset Management LLC increased its stake in DaVita by 8.7% in the 3rd quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock valued at $79,916,000 after buying an additional 67,970 shares during the last quarter. Finally, Northern Trust Corp increased its stake in DaVita by 15.7% in the 3rd quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after buying an additional 113,508 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DaVita

In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock worth $16,551,071 in the last three months. Company insiders own 1.40% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of several analyst reports. Barclays initiated coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price objective for the company. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Truist Financial boosted their price objective on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. Finally, StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, DaVita has an average rating of “Moderate Buy” and an average target price of $118.50.

DaVita Trading Up 0.5 %

Shares of DVA traded up $0.73 during midday trading on Friday, hitting $133.50. The stock had a trading volume of 477,665 shares, compared to its average volume of 798,575. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The firm has a market cap of $11.71 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 1.18 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The stock’s 50 day moving average is $131.89 and its 200 day moving average is $110.16.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.11 EPS. As a group, analysts forecast that DaVita Inc. will post 9.23 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.